… A phase II clinical trial examining erlotinib … a phase III trial (BR.21) examining erlotinib
monotherapy 150 mg/day in the same type of patients is in progress. In the phase II clinical trial, 57 …

… Gefitinib showed a progression-free survival (PFS) advantage over chemotherapy as a
first-line therapy in 3 randomized phase III trials in patients with EGFR mutant lung …

… in improving the efficacy of erlotinib. The Cancer and Leukemia Group B trial 30406 was
a randomized phase 2 clinical trial that investigated erlotinib alone or with carboplatin and …

… The potential for combining EGFR TKIs with cytotoxic drugs was initially investigated in four
randomized phase III trials. In these studies, concurrent administration of erlotinib or gefitinib …

… To some extent, the conclusion of the present study was almost the same as that of the
earlier randomised phase II study, in which gefitinib and erlotinib showed similar efficacy and …

… erlotinib has proven efficacy and tolerability in second-line NSCLC. We designed the phase
3, … ; BO18192) study to assess use of erlotinib as maintenance therapy in patients with non-…

… and in combination with erlotinib; it demonstrated a … , randomized phase II trial to prospectively
compare the progression-free survival (PFS) of erlotinib plus tivantinib with erlotinib plus …

… trial compared erlotinib with placebo in previously treated patients with advanced NSCLC and
showed significantly superior survival for erlotinib… conducted a randomized phase II trial to …

… We hypothesized that erlotinib would be efficacious in the … with erlotinib in the EGFRm-positive
subgroup warrants further evaluation. A phase III US intergroup trial of adjuvant erlotinib …

… Our prospective, randomized phase II study of patients with NSCLC who previously … that
demonstrated entinostat combined with erlotinib enhances the effect of erlotinib alone and can …